| Stereochemistry | RACEMIC |
| Molecular Formula | C11H16N2O2 |
| Molecular Weight | 208.2569 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCC1=CC=C2OCOC2=C1)NN
InChI
InChIKey=IBWPUTAKVGZXRB-UHFFFAOYSA-N
InChI=1S/C11H16N2O2/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10/h4-6,8,13H,2-3,7,12H2,1H3
| Molecular Formula | C11H16N2O2 |
| Molecular Weight | 208.2569 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s. Safrazine and electroconvulsive therapy were shown to be effective in the treatment of antidepressant-resistant depressions (ARD) but had the drawbacks of the high incidence of moderate or severe adverse reactions and high relapse rates, respectively. The use of safrazine was discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
PubMed
Sample Use Guides
Nocturnal periodic hypoxemia occurring in a 25-year-old Duchenne muscular dystrophy patient under NIPPV control was successfully treated with monoamine oxydase inhibitor (MAOI), safrazine hydrochloride. Five mg of safrazine hydrochloride was administered before sleep, and the periodic hypoxemia disappeared within 14 days.
Route of Administration:
Oral
